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Abstract
Background The IMPACT SHPT [Improved Manage-
ment of Intact Parathyroid Hormone (iPTH) with Pari-
calcitol-Centered Therapy Versus Cinacalcet Therapy with
Low-Dose Vitamin D in Hemodialysis Patients with Sec-
ondary Hyperparathyroidism] study compared the effec-
tiveness of paricalcitol and cinacalcet in the management
of secondary hyperparathyroidism in haemodialysis
patients but did not report the costs or cost effectiveness of
these treatments.
Aim The aim of this study was to compare the cost
effectiveness of a paricalcitol-based regimen versus cina-
calcet with low-dose vitamin D for management of sec-
ondary hyperparathyroidism in haemodialysis patients
from a US payer perspective, using a 1-year time horizon.
Methods This was a post hoc cost-effectiveness analysis
of data collected for US patients enrolled in the
IMPACT SHPT study—a 28-week, randomized, open-
label, phase 4, multinational study (ClinicalTrials.gov
identifier: NCT00977080). Patients eligible for the
IMPACT SHPT study were aged C18 years with stage 5
chronic kidney disease, had been receiving maintenance
haemodialysis three times weekly for at least 3 months
before screening and were to continue haemodialysis dur-
ing the study. Only US patients who reached the evaluation
period (weeks 21–28) were included in this secondary
analysis. US subjects in the IMPACT SHPT study were
randomly assigned to receive intravenous paricalcitol, or
oral cinacalcet plus fixed-dose intravenous doxercalciferol,
for 28 weeks. Patients in the paricalcitol group could also
receive supplemental cinacalcet for hypercalcaemia. The
primary effectiveness endpoint in the IMPACT SHPT
study was the proportion of subjects who achieved a mean
intact parathyroid hormone (iPTH) level of 150–300
pg/mL during the evaluation period. In this secondary
analysis, we estimated the incremental cost-effectiveness
ratio (ICER), comparing paricalcitol-treated patients with
cinacalcet-treated patients on the basis of this primary
endpoint and several secondary endpoints. Costs were
estimated by examining the dosage of the study drug
(paricalcitol or cinacalcet) and phosphate binders used by
each participant during the trial. Nonparametric bootstrap
analysis was used to examine the accuracy of the ICER
point estimates.
Results The percentages of patients achieving the treat-
ment goal of a mean iPTH level between 150–300 pg/mL
during weeks 21–28 of therapy were 56.9 % in the pari-
calcitol group and 34.0 % in the cinacalcet group (a dif-
ference of 23 %, p = 0.0235). Paricalcitol was also more
effective for each of the secondary endpoints. When
annualized, the total drug costs were US$10,153 in the
paricalcitol group and US$15,967 in the cinacalcet group, a
difference of US$5,814 (57.3 %, p = 0.0053). Because the
paricalcitol-based treatment was less expensive and more
effective, it was ‘dominant’, compared with cinacalcet, in
this cost-effectiveness analyses. In our bootstrap analysis,
99.1 % of bootstrap replicates for the ICER of the primary
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endpoint fell within the lower right quadrant of the cost-
effectiveness plane—where paricalcitol is considered
dominant. For all of the other endpoints, paricalcitol was
dominant in 100 % of replicates.
Conclusion On the basis of dosing and effectiveness data
from US patients in the IMPACT SHPT study, we found
that a regimen of intravenous paricalcitol was more cost
effective than cinacalcet plus low-dose vitamin D in the
management of iPTH in patients with SHPT requiring
haemodialysis.
1 Introduction
Because of the aging of the population and the increased
prevalence of hypertension, diabetes and obesity, chronic
kidney disease (CKD) is impacting a greater proportion of
US society [1–3]. Many patients with CKD progress to
end-stage renal disease (ESRD) and require dialysis. As a
result, CKD is very expensive for individual patients,
insurance companies and Medicare [4]. Many CKD
patients also develop elevated intact parathyroid hormone
(iPTH) levels or secondary hyperparathyroidism (SHPT),
which further adds to the burden of their disease [5]. SHPT
results in imbalances in serum calcium and phosphorous
levels, and in alternations in vitamin D metabolism, and
can lead to renal osteodystrophy, fractures, cardiovascular
disease and even death [6–10].
Guidelines for the management of SHPT have been
published by the National Kidney Foundation (NKF) and
recommend control of iPTH levels with vitamin D receptor
(VDR) activators [11, 12]. The 2003 Kidney Disease
Outcomes Quality Initiative (KDOQI) recommended a
serum iPTH target of 150–300 pg/mL, while the 2009
Improving Global Outcomes (KDIGO) guidelines sug-
gested an iPTH goal of 2–9 times the upper limit of normal
(which corresponds to a range of 130–600 pg/mL) [11].
Control of iPTH levels with VDR activators—which
include calcitriol, doxercalciferol, paricalcitol and alfacal-
cidol—is associated with improved outcomes [13, 14].
Among the VDR activators, the evidence is strongest for
paricalcitol, which is associated with reduced hospitaliza-
tion and improved survival [15–17]. Cinacalcet, a calcim-
imetic agent, is also effective in reducing PTH levels and,
when used concomitantly with low-dose vitamin D, it may
minimize hypercalcaemia [18, 19].
The effectiveness of paricalcitol and cinacalcet was
compared in the recent multinational IMPACT SHPT
(Improved Management of iPTH with Paricalcitol-Cen-
tered Therapy Versus Cinacalcet Therapy with Low-dose
Vitamin D in Hemodialysis Patients with Secondary
Hyperparathyroidism) study. Paricalcitol was found to be
superior to cinacalcet plus low-dose vitamin D in
controlling iPTH levels [20]. While the IMPACT SHPT
study was important for understanding the comparative
effectiveness of the two drugs, knowing the cost effec-
tiveness is also essential. A recent secondary analysis of the
IMPACT SHPT data found that a paricalcitol-based regi-
men was less expensive than cinacalcet from a global
perspective (with costs expressed in Euros) [21]. However,
because of differences in international drug pricing, these
data may not be relevant to US patients, clinicians and
payers. Moreover, what is needed most for evidence-based
decision making is a direct comparison of the cost effec-
tiveness of these agents.
Here, we provide an examination of the US patients in
the IMPACT SHPT study, and we extend the previous
analysis by examining not just the costs but also the cost
effectiveness of paricalcitol compared with cinacalcet.
While there are other studies that have compared the cost
effectiveness of treatments for SHPT, none have compared
paricalcitol and cinacalcet directly [22, 23]. Thus, the
objective of this study was to evaluate, from a payer per-
spective, the cost effectiveness of paricalcitol versus cin-
acalcet with low-dose vitamin D for management of SHPT
in haemodialysis patients in the USA.
2 Methods
This was a secondary cost-effectiveness analysis of data
from US patients collected during the IMPACT SHPT study.
The methods of the IMPACT SHPT study are described in
detail elsewhere [24]. In brief, the IMPACT SHPT study was
a 28-week, randomized, open-label, phase 4, multinational
study (ClinicalTrials.gov identifier: NCT00977080). US
subjects were randomly assigned to receive intravenous
paricalcitol (the paricalcitol group), or oral cinacalcet plus
fixed-dose intravenous doxercalciferol, for 28 weeks.
Patients in the paricalcitol group could also receive supple-
mental cinacalcet for hypercalcaemia [used only if the serum
calcium level was C10.5 mg/dL (2.61 mmol/L) in two
consecutive blood tests in the presence of a high iPTH level].
At weeks 21–28 (the ‘evaluation period’), patients were
evaluated for clinical response. For the purposes of this
secondary analysis, only those patients who reached the
evaluation period were included.
The primary effectiveness endpoint in the
IMPACT SHPT study was the proportion of subjects who
achieved a mean iPTH level of 150–300 pg/mL during the
evaluation period. We used this endpoint as our primary
effectiveness input in estimating cost effectiveness. We
also included secondary effectiveness endpoints, namely
the proportion of subjects achieving either a C30 or C50 %
reduction in the iPTH level, the proportion of subjects with
a normal serum calcium level (8.4–10.5 mg/dL) and the
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proportion of subjects with both an iPTH level of
150–300 pg/mL and a calcium level of 8.4–10.5 mg/dL
during the evaluation period.
Costs were not measured directly in the IMPACT SHPT
study but were estimated here by examining the dosage of
the study drug (paricalcitol or cinacalcet) and phosphate
binders used by each participant during the trial. Included
in the cost of the study drugs was any supplemental cina-
calcet administered to patients in the paricalcitol group and
the use of fixed-dose intravenous doxercalciferol in the
cinacalcet group. To estimate costs, we multiplied utiliza-
tion by the unit price for each drug, which was based on the
2012 wholesale acquisition cost, to get the total cost per
patient in US dollars. The wholesale acquisition cost was
obtained from AnalySource, an online source of drug
pricing data from First Databank, Inc. (San Francisco, CA,
USA), and is shown in Table 1. We assumed that the
dosage reached in the evaluation period was the mainte-
nance dose, and we estimated annual costs by extrapolating
the costs observed during the evaluation period. These
annualized costs were then incorporated into our cost-
effectiveness analysis so that the results assumed a 1-year
time horizon.
Descriptive statistics, including means with standard
deviations and percentages, were used to characterize the
clinical and cost data in each group. Differences between
demographic and baseline characteristics, costs and effec-
tiveness outcomes were examined using chi-squared and
Student t tests as appropriate. All statistical tests were two-
tailed, with p values of \0.05 considered statistically sig-
nificant. The data were summarized and analysed using SAS
version 11.0 software (SAS Institute, Cary, NC, USA).
Incremental cost-effectiveness ratios (ICERs) were cal-
culated for the primary and secondary effectiveness out-
comes (separately). The ICER represents a ratio of the
difference in costs (the numerator) in the paricalcitol group
relative to the cinacalcet group to the difference in effects
(the denominator) of the two treatments. The formula is as
follows: ICER = (Cp - Cc)/(Ep - Ec), where Cp repre-
sents the total drug cost in the paricalcitol group and Cc
represents the total drug cost in the cinacalcet group, and
where Ep represents the effectiveness in the paricalcitol
group and Ec represents the effectiveness in the cinacalcet
group. Here, effectiveness is the proportion of patients in
each group who achieved that particular endpoint.
To estimate the 95 % confidence intervals for the
ICERs, we simulated 1,000 non-parametric bootstrap rep-
licates by sampling with replacement from the original
dataset. For each of the replicates, we calculated the ICER.
The 95 % confidence intervals were determined by the
2.5th and 97.5th percentiles of all the bootstrap replicates.
We also determined the proportion of bootstrap replicates
that fell in each quadrant of the standard cost-effectiveness
plane. We used this approach for both the primary effec-
tiveness outcome and each of the secondary effectiveness
outcomes.
3 Results
Table 2 describes the demographic and baseline charac-
teristics of the patients in each treatment group. The two
groups were comparable. The majority of patients were
male—60.8 and 59.6 % in the paricalcitol and cinacalcet
treatment groups, respectively—and their mean ages were
61.0 and 60.7 years, respectively. On average, the patients
had been on dialysis for 3.9 years. Baseline laboratory
values and the use of concomitant medications did not
differ significantly between the groups. However, a sig-
nificantly greater proportion of subjects in the paricalcitol
group had angina and left ventricular hypertrophy.
3.1 Effectiveness
The clinical results of the IMPACT SHPT study are pre-
sented in detail elsewhere [20]. The primary endpoint was
the percentage of patients achieving the treatment goal of a
mean iPTH level between 150–300 pg/mL during weeks
21–28 of therapy per stratum. As shown in Table 2, among
US patients, 29 (56.9 %) in the paricalcitol group and 16
(34.0 %) in the cinacalcet group reached this endpoint (a
difference of 23 %, p = 0.0235). Similarly, greater pro-
portions of patients in the paricalcitol group than in the
cinacalcet group achieved a [30 % reduction in the iPTH
level (84.3 versus 48.9 %, a difference of 35 %, p = 0.0002)
and a [50 % reduction in the iPTH level (64.7 versus
21.3 %, a difference of 43 %, p = 0.0001). Further, com-
pared with those in the cinacalcet group, a greater proportion
Table 1 Unit prices of drugs included in the analysis











a Unit prices were based on 2012 wholesale acquisition costs and
were obtained from AnalySource, an online source of drug pricing
data from First Databank, Inc. (San Francisco, CA, USA)
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of those in the paricalcitol group maintained a normal serum
calcium level (92.2 versus 53.2 %, a difference of 39 %,
p \ 0.0001). Finally, more patients in the paricalcitol group
than in the cinacalcet group both met the primary endpoint
(an iPTH level of 150–300 pg/mL) and were normocalcae-
mic (52.9 versus 17.0 %, a difference of 36 %, p = 0.0002).
3.2 Costs
When annualized on the basis of the evaluation period,
the mean total drug costs were US$10,153 in the
paricalcitol group and US$15,967 in the cinacalcet
group, a difference of US$5,814 (57.3 %, p = 0.0053),
as shown in Table 3. The mean annualized costs of
phosphate binders were US$7,173 and US$6,703 in the
paricalcitol and cinacalcet groups, respectively, which
was not statistically different (p = 0.7645). However, the
mean annualized cost of the study drug for those in the
cinacalcet group was three times that in the paricalcitol
group (US$2,979 and US$9,264 in the paricalcitol and
cinacalcet groups, respectively, a difference of US$6,285,
p \ 0.0001).





hormone, SD standard deviation
a Differences between groups
were considered statistically
significant (indicated by bold
text) if p \ 0.05 on the basis of
Pearson’s chi-squared test or
Student’s t test
b Not all subjects had a baseline
value recorded for this item—
n = 36 in the paricalcitol group
and n = 36 in the cinacalcet
group
c Not all subjects had a baseline
value recorded for this item—
n = 46 in the paricalcitol group
and n = 50 in the cinacalcet
group
Characteristic Paricalcitol Cinacalcet p valuea
Subjects [n] 51 47
Age [years; mean ± SD] 61.0 ± 11.5 60.7 ± 11.6 0.8984
Male [n (%)] 31 (60.8) 28 (59.6) 0.9027
Race [n (%)] 0.3147
White 24 (47.1) 26 (55.3)
Black 25 (49.0) 19 (40.4)
Other 2 (4.0) 2 (4.3)
Hispanic [n (%)] 11 (21.6) 13 (27.7) 0.4836
Diabetes [n (%)]
Type 1 5 (9.8) 1 (2.1) 0.1133
Type 2 33 (64.7) 26 (55.3) 0.3429
Cardiovascular disease [n (%)]
Angina 7 (13.7) 1 (2.1) 0.0362
Myocardial infarction 10 (19.6) 4 (8.5) 0.1168
Coronary artery disease 20 (39.2) 13 (27.7) 0.2265
Left ventricular hypertrophy 11 (21.6) 2 (4.3) 0.0116
Duration of dialysis [years; mean ± SD] 3.9 ± 3.3 3.9 ± 3.3 0.9948
Blood pressure [mmHg; mean ± SD]
Systolic 142.8 ± 26.1 149.4 ± 24.7 0.2016
Diastolic 72.7 ± 12.9 76.5 ± 15.2 0.1839
Concomitant medications [n (%)]
Angiotensin-converting enzyme inhibitors 20 (39.2) 18 (38.3) 0.9258
Angiotensin II receptor blockers 9 (17.6) 7 (14.9) 0.7126
Beta blockers 35 (68.6) 27 (57.4) 0.2514
Calcium channel blockers 26 (51.0) 24 (51.1) 0.9934
Diuretics 16 (31.4) 9 (19.1) 0.1655
Erythropoiesis-stimulating agents 43 (84.3) 38 (80.8) 0.6511
Baseline laboratory values
Serum iPTH level [pg/mL; mean ± SD] 516.6 ± 147.9 524.3 ± 149.7 0.7984
Corrected calcium level [mg/dL; mean ± SD] 9.0 ± 0.5 9.1 ± 0.4 0.5402
Phosphorus level [mg/dL; mean ± SD] 4.8 ± 1.0 5.0 ± 1.0 0.4789
Alkaline phosphatase level [IU/L; mean ± SD] 111.9 ± 52.8 126.9 ± 52.4 0.1617
Bone-specific alkaline phosphatase level [U/L; mean ± SD] 35.7 ± 15.8 41.7 ± 26.7 0.1801
25-hydroxy vitamin D level [ng/mL; mean ± SD]b 23.0 ± 14.0 23.7 ± 9.7 0.8148
Creatinine level [mg/dL; mean ± SD]c 8.1 ± 2.3 9.0 ± 2.5 0.0994
Albumin level [g/dL; mean ± SD] 4.0 ± 0.2 4.0 ± 0.3 0.6989
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3.3 Cost Effectiveness
Table 4 provides the results of our cost-effectiveness ana-
lysis. The table includes the difference between the pari-
calcitol and cinacalcet groups in terms of the mean total
drug costs (based on data in Table 3). This is the numerator
in the ICER calculations. Because paricalcitol was less
expensive, the difference in cost was negative (representing
the savings associated with paricalcitol). Note that the costs
were the same for each of the ICER calculations. Table 3
also shows the difference between the paricalcitol and
cinacalcet groups in the proportions of patients who
responded, based on each endpoint included (based on data
in Table 2). This is the denominator in the ICER
calculation.
The paricalcitol-based treatment was less expensive and
more effective than the cinacalcet-based treatment, regard-
less of which effectiveness measure we examined. In phar-
macoeconomic terms, this means that paricalcitol was
‘dominant’, compared with cinacalcet. In each case, the
ICER was negative. For example, for the primary endpoint
(an iPTH level within the recommend range of 150–300 pg/
mL), the ICER was -US$25,389. Because negative ICERs
are difficult to interpret, the common practice is just to report
that the treatment is ‘dominant’ (as shown in Table 4) rather
than to report the negative ICER value. The 95 % confidence
interval for the ICER of the primary endpoint, derived from
the bootstrap replicates, was -US$133,121 to -US$5,820.
Note that the interval does not include zero. The final column
in Table 4 provides additional results from the bootstrap
analysis—specifically, the proportion of bootstrap replicates
in which paricalcitol was dominant. For the primary end-
point, paricalcitol was dominant in 99.1 % of replicates. For
all of the other endpoints, paricalcitol was dominant in
100 % of replicates.
Figure 1 is a scatterplot of all 1,000 bootstrap replicates,
with the x-axis representing the incremental cost and the y-
axis representing the incremental effectiveness of the
paricalcitol-based regimen compared with the cinacalcet-
based regimen, where effectiveness is the proportion of
subjects reaching an iPTH level of 150–300 pg/mL. All
replicates fell within two quadrants of the cost-effective-
ness plane. The lower right quadrant, where paricalcitol
was both less expensive and more effective than cinacalcet
(i.e. dominant) contained 99.1 % of the replicates. The
lower left quadrant, where paricalcitol was less expensive
but less effective, contained 0.9 % of replicates. For each
of the secondary endpoints, the scatterplots (not shown)
contained 100 % of bootstrap replicates in the lower right
quadrant—where paricalcitol was dominant.
Table 3 Effectiveness and costs by treatment group
Characteristic Paricalcitol Cinacalcet p valuea
Subjects [n] 51 47
Effectiveness [n (%)]
Primary endpoint
iPTH level 150–300 pg/mLb 29 (56.9) 16 (34.0) 0.0235
Secondary endpoints
C30 % reduction in iPTH levelc 43 (84.3) 23 (48.9) 0.0002
C50 % reduction in iPTH leveld 33 (64.7) 10 (21.3) <0.0001
Calcium level 8.4–10.5 mg/dLe 47 (92.2) 25 (53.2) <0.0001
iPTH level 150–300 pg/mL and calcium level 8.4–10.5 mg/dLf 27 (52.9) 8 (17.0) 0.0002
Costs [US$; mean ± SD]g
Cost of study drugs 2,979 ± 2,422 9,264 ± 7,275 <0.0001
Cost of phosphate binders 7,173 ± 6,987 6,703 ± 8,380 0.7645
Total drug cost 10,153 ± 7,751 15,967 ± 11,734 0.0053
iPTH intact parathyroid hormone, SD standard deviation
a Differences between groups were considered statistically significant (indicated by bold text) if p \ 0.05 on the basis of Pearson’s chi-squared
test or Student’s t test
b Proportion of subjects achieving a mean iPTH level of 150–300 pg/mL during the evaluation period (weeks 21–28)
c Proportion of subjects achieving C30 % reduction in the mean iPTH level during the evaluation period compared with baseline
d Proportion of subjects achieving C50 % reduction in the mean iPTH level during the evaluation period compared with baseline
e Proportion of subjects with a mean calcium level of 8.4–10.5 mg/dL during the evaluation period
f Proportion of subjects achieving both a mean iPTH level of 150–300 pg/mL and a mean calcium level of 8.4–10.5 mg/dL during the evaluation
period
g Costs were annualized on the basis of dosages in the evaluation period
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4 Discussion
In this secondary analysis of US patients enrolled in the
IMPACT SHPT study, we found that intravenous
paricalcitol-based therapy with or without supplemental
cinacalcet was more cost effective than the combination of
cinacalcet and low-dose vitamin D in the management of
iPTH and calcium levels in patients with SHPT requiring
Table 4 Incremental cost-effectiveness results
Effectiveness measure Difference in
costs







(Cp - Cc)/(Ep - Ec)
Probability that
paricalcitol is dominant [%]c
Primary endpoint
iPTH level 150–300 pg/mLd -5,814 0.23 Dominant 99.1
Secondary endpoints
C30 % reduction in iPTH levele -5,814 0.35 Dominant 100
C50 % reduction in iPTH levelf -5,814 0.43 Dominant 100
Calcium level 8.4–10.5 mg/dLg -5,814 0.39 Dominant 100
iPTH level 150–300 pg/mL and
calcium level 8.4–10.5 mg/dLh
-5,814 0.36 Dominant 100
Cc cost in the cinacalcet group, Cp cost in the paricalcitol group, Ec effectiveness in the cinacalcet group, Ep effectiveness in the paricalcitol
group, ICER incremental cost-effectiveness ratio, iPTH intact parathyroid hormone
a Difference in the total annualized drug cost between treatment groups [i.e. the cost in the paricalcitol group (Cp) minus the cost in the
cinacalcet group (Cc)]. This is the numerator of the ICER. Note that the difference is the same regardless of which measure of effectiveness is
analysed
b Difference in the effectiveness endpoint between treatment groups [i.e. the proportion of patients achieving the endpoint in the paricalcitol
group (Ep) minus the proportion of patients achieving the endpoint in the cinacalcet group (Ec)]. This is the denominator of the ICER
c Derived from the bootstrap analysis
d Proportion of subjects achieving a mean iPTH level of 150–300 pg/mL during the evaluation period (weeks 21–28)
e Proportion of subjects achieving C30 % reduction in the mean iPTH level during the evaluation period compared with baseline
f Proportion of subjects achieving C50 % reduction in the mean iPTH level during the evaluation period compared with baseline
g Proportion of subjects with a mean calcium level of 8.4–10.5 mg/dL during the evaluation period





































Quadrant in which 
paricalcitol is dominated by 
cinacalcet
Quadrant in which 
paricalcitol dominates 
cinacalcet
Quadrant in which paricalcitol is 
more effective and more 
expensive then cinacalcet
Quadrant in which paricalcitol is 
less effective and less expensive 
than cinacalcet
Fig. 1 Scatterplot of 1,000 bootstrap replicates showing the incre-
mental cost and incremental effectiveness of the paricalcitol regimen
compared with the cinacalcet-based regimen, where effectiveness is
the proportion of subjects reaching an intact parathyroid hormone
(iPTH) level of 150–300 pg/mL (the primary endpoint). All simula-
tion results fell within two quadrants of the cost-effectiveness plane:
(1) the lower right quadrant, where the paricalcitol regimen is both
less expensive and more effective than cinacalcet (i.e. dominant),
containing 99.1 % of the replicates; and (2) the lower left quadrant,
where the paricalcitol regimen is less expensive but less effective,
containing 0.9 % of the replicates
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haemodialysis. Whether effectiveness was measured in
terms of the proportions of patients meeting the iPTH
target of 150–300 pg/mL (the primary outcome), or in any
of several other ways (the proportions of patients with C30
or C50 % reductions in iPTH levels, the proportions of
patients who were normocalcaemic, or the proportions of
patients who were normocalcaemic and also met the iPTH
target), the paricalcitol-based regimen was more effective
than the cinacalcet-based regimen. Similarly, when con-
sidering both the cost of the study drug and the phosphate
binders, the paricalcitol-based regimen was less expensive.
As a result, the paricalcitol-based regimen was dominant,
compared with cinacalcet.
We used bootstrap analysis to provide a measure of the
degree of error around our ICER point estimates. In over
99 % of bootstrap replicates, regardless of the effectiveness
endpoint incorporated into the denominator of the ICER,
our result remained dominant for paricalcitol over cina-
calcet. These results provide a high degree of confidence
about the precision of our results.
Our findings are consistent with those of other studies.
Using data from all patients in the multinational
IMPACT SHPT study, and including those who received
either intravenous or oral regimens of paricalcitol or cin-
acalcet, we previously found that the annualized mean total
drug costs (based on 2011 data) were €5387 in the pari-
calcitol group and €6870 in the cinacalcet group (a dif-
ference of €1492, p = 0.0395) [21]. Similarly, a post hoc
analysis of the ACHIEVE study found that the average
medication costs were 48 % higher (data from 2006) in
patients treated with cinacalcet plus low-dose vitamin D
than in those receiving either paricalcitol or doxercalciferol
(US$5,501 versus US$3,709 in each group, respectively)
[23]. Though not a cost-effectiveness analysis, the only
other study that examined costs in paricalcitol- and cina-
calcet-treated patients focused on costs related to para-
thyroidectomy—which occurred less frequently in those
treated with paricalcitol [25].
The implications of our results are important for
patients, health care providers and payers. Under recent
Medicare rules, the reimbursement of care for dialysis
patients is capitated. By 2016, both oral and injectable
medications will be included in a single ‘all-inclusive
bundle’ payment to providers. Under this scenario, pro-
viders are incentivized to prescribe the most cost-effective
therapies. Our results suggest that a paricalcitol-based
regimen is more cost effective than cinacalcet, and this
may mean both improved outcomes for patients and
reduced costs for providers and payers.
Our findings should be interpreted with an understand-
ing of the limitations of our analysis. This was a post hoc
analysis of data from the randomized, open-label, phase 4,
multinational IMPACT SHPT study. The limitations of the
IMPACT SHPT study have been described elsewhere [20,
24]. Here, we focus primarily on limitations that may have
influenced the cost-effectiveness analysis. First, both the
cost and effectiveness estimates we incorporated into our
analysis were influenced by the IMPACT study protocol.
For example, although they were based on approved
labelling, the dosing of study drugs and phosphate binders
in the IMPACT study may not have reflected actual prac-
tice for all patients in the USA. Further, like most clinical
trials, the IMPACT SHPT study was short-term
(28 weeks). Actual treatment of SHPT in patients on hae-
modialysis is longer term. We attempted to account for this
by using a 1-year time horizon for our cost-effectiveness
analysis. We annualized costs on the basis of the evaluation
period, where dosing had stabilized. We also made the
assumption that effectiveness did not change once dosing
was stabilized. It is important to note that in the IMPACT
study, patients who dropped out before reaching the eval-
uation period were not included in the analysis. However,
the dropout rates were low for a clinical trial (approxi-
mately 20 % in the intravenous paricalcitol group and
30 % in the intravenous cinacalcet group).
The actual drug costs included in our analysis were not
part of the IMPACT SHPT study data, but instead were
estimated post hoc on the basis of the dosages used by each
patient. We estimated the costs of the study drugs and
phosphate binders by applying unit costs derived from an
external database. This approach may have resulted in
slightly different estimates than would have been obtained
with actual costs. However, it is not likely that such dif-
ferences would have changed either the direction or the
magnitude of our results.
It is important to note that our cost analysis was restricted
to study drugs and phosphate binders reported in the
IMPACT SHPT study. An advantage of our analysis was
that all of the cost and effectiveness results were from the
same set of patients. Many cost-effectiveness studies, par-
ticularly those that involve modelling, use heterogeneous
sources of data for costs and effectiveness and, because of
that, they may be subject to bias. However, a limitation of our
approach was that certain costs were not included, because
they were not collected or recorded in the IMPACT SHPT
study. For example, the utilization of laboratory tests, fre-
quency of hospitalizations or physician office visits, and
other health care utilization costs were not included. Inclu-
sion of such costs could provide a more complete under-
standing of the cost effectiveness of paricalcitol and
cinacalcet, particularly since we assumed a payer perspec-
tive. These additional costs are generally associated with
differences in treatment effectiveness, adverse effects or
monitoring. However, in the IMPACT SHPT study, the
paricalcitol-based regimen was more effective than the cin-
acalcet-based regimen, and while the reported serious and
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severe adverse events were no different, adverse events
leading to treatment discontinuation in patients receiving
intravenous therapy were significantly less common in the
paricalcitol group than in the cinacalcet group [20]. More-
over, there is no evidence that monitoring requirements are
different between cinacalcet and paricalcitol. Therefore, it is
unlikely that the direction of our results would have changed
if those costs had been included.
One last potential limitation of our analysis relates to the
generalizability of the population studied. A slightly higher
percentage of US patients who enrolled in the
IMPACT SHPT were Black or Hispanic, compared with
the general population of ESRD patients. Data from the
United States Renal Data System (USRDS) suggests that
36.1 % of ESRD patients in the USA are black and 15.1 %
are Hispanic [26]. Across both groups in the
IMPACT SHPT study, 44.9 % of US patients were black
and 24.5 % were Hispanic. While this difference is small,
because the response to therapy may differ by race and
ethnicity, it should be considered.
5 Conclusion
On the basis of dosing and effectiveness data from US
patients in the IMPACT SHPT study, we found that a regi-
men of intravenous paricalcitol was more cost effective than
cinacalcet plus low-dose vitamin D in the management of
iPTH in patients with SHPT requiring haemodialysis.
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